Cargando…
Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries
Over the past decade, the use of biologics has significantly changed the management of rheumatoid arthritis (RA). Biologics selectively target components of the immune system, resulting in better disease control. However, the growing use of biologics in RA has increased safety concerns among rheumat...
Autores principales: | Codreanu, Catalin, Damjanov, Nemanja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315467/ https://www.ncbi.nlm.nih.gov/pubmed/25670881 http://dx.doi.org/10.2147/BTT.S68949 |
Ejemplares similares
-
Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients
por: Pavelka, Karel, et al.
Publicado: (2020) -
Area of Residence and Socioeconomic Factors Reduce Access to Biologics for Rheumatoid Arthritis Patients in Romania
por: Codreanu, Cătălin, et al.
Publicado: (2018) -
Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review
por: Lau, Chak Sing, et al.
Publicado: (2017) -
Analysis of the Indirect Costs of Rheumatoid Arthritis in Romania
por: Codreanu, Cătălin, et al.
Publicado: (2019) -
Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
por: Popescu, Claudiu Costinel, et al.
Publicado: (2022)